SELECTED IMPORTANT SAFETY INFORMATION: KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. CONTINUE READING BELOW >


is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.


Patient support, financial and affordability solutions

Hands interlocked graphic.

Patient Loyalty Program†§

Bayer is committed to helping your patients start and stay on therapy regardless of changes in their commercial health insurance coverage status.

Eligible patients can receive KOVALTRY® at no cost if they experience gaps or changes with insurance coverage.

Calendar graphic.

Free Trial Program‡§

  • All patients new to KOVALTRY can receive 1-month of free therapy.
  • Selected product is delivered to your patient's home.
  • Any patient new to KOVALTRY is able to participate, regardless of type of insurance or if they have insurance.
Phone operator graphic.

$0 Co-Pay Program*†

  • Eligible commercially insured patients can pay as low as $0 per prescription, regardless of income* (up to $20,000 in co-pay assistance per year).
  • Assistance is awarded per patient. Multiple members of the same household can apply.
  • Patients can enroll here or in one short phone call to 1-800-288-8374.

Click here to submit a $0 prescription claim under your patient's medical benefit.

Lab vial graphic.

Free Sample Program

With the program, you can:

  • Start your patients on KOVALTRY right away.
  • Provide your patients with a limited supply of KOVALTRY at no cost.

Ordering a sample is simple:

  • Your sales representative will process your sample request.
  • Orders will be shipped within 24-48 hours.
Contact your rep to request a free sample
Access Services by Bayer Logo.

to prescribe KOVALTRY to your patient and enroll them in Access Services by Bayer.

the Access Services patient support request form.

Speak with a health insurance expert. Multiple languages are available, including Spanish.

Alt tag

If your patients cannot afford their prescription medication, Bayer may be able to help.

The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday–Friday, 9:00 AM–6:00 PM EST, or visit the foundation website at to see if they might qualify for assistance.

KOVALTRY is 100% covered under the Medicare medical benefit nationally¶#



KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY is not indicated for the treatment of von Willebrand disease.


KOVALTRY is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY if symptoms occur and seek immediate emergency treatment.

KOVALTRY may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation has occurred following administration of KOVALTRY. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and pyrexia, headache, and rash.

For additional important risk and use information, please see full Prescribing Information.